Form 4: AQST Officer Sells 10,000 Shares

Peter E. Boyd, an officer and director of Aquestive Therapeutics, Inc., sold 10,000 shares of common stock at $6.30 per share.

Summary

• Peter E. Boyd, SVP IT, HR, & Communications and Director at Aquestive Therapeutics, Inc. (AQST), reported a sale of common stock.
• On September 26, 2025, Boyd disposed of 10,000 shares of AQST common stock.
• The shares were sold at a price of $6.30 per share.
• Following this transaction, Boyd beneficially owns 278,323 shares of common stock.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The sale of shares by an insider, even under a 10b5-1 plan, is generally neutral to slightly negative as it represents a reduction in insider ownership. However, the pre-scheduled nature mitigates strong negative sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not necessarily based on new, non-public information.

Negatives

• An officer and director sold 10,000 shares of common stock, which could be perceived as a lack of confidence by some investors, despite the 10b5-1 plan.

Future Outlook

There are no forward-looking statements or guidance provided in this filing.

Industry Context

This announcement pertains to a company-specific insider transaction and does not directly relate to broader industry trends or competitor activities.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some may view it as a routine financial planning event due to the 10b5-1 plan, while others might see it as a signal of reduced confidence.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Peter E. Boyd, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership